Substance / Medication

Tranylcypromine

Overview

Active Ingredient
tranylcypromine
RxNorm CUI
10734

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

48 trials linked to this intervention

48
Total Trials
5
Recruiting
17
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression.
Ricken Roland, Ulrich Sven, Schlattmann Peter et al. · Eur Neuropsychopharmacol · 2017
PMID: 28579071Meta-Analysis
Efficacy of Tranylcypromine in Bipolar Depression: A Systematic Review.
Heijnen Willemijn T, De Fruyt Jürgen, Wierdsma André I et al. · J Clin Psychopharmacol · 2015
PMID: 26479223Meta-Analysis
Withdrawal and discontinuation phenomena associated with tranylcypromine: a systematic review.
Gahr M, Schönfeldt-Lecuona C, Kölle M A et al. · Pharmacopsychiatry · 2013
PMID: 23359339Meta-Analysis
Intoxications with the monoamine oxidase inhibitor tranylcypromine: an analysis of fatal and non-fatal events.
Gahr Maximilian, Schönfeldt-Lecuona Carlos, Kölle Markus A et al. · Eur Neuropsychopharmacol · 2013
PMID: 23791433Meta-Analysis
Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder.
Nardi Antonio E, Lopes Fabiana L, Valença Alexandre M et al. · Psychiatry Res · 2010
PMID: 20036427RCT
Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression.
Tulen Joke H M, Volkers Anita C, van den Broek Walter W et al. · J Clin Psychopharmacol · 2006
PMID: 16974207RCT
Functional efficacy of the MAO-B inhibitor safinamide in murine substantia nigra pars compacta dopaminergic neurons in vitro: A comparative study with tranylcypromine.
Zarrilli Beatrice, Giacomet Cecilia, Cossa Francesca et al. · Parkinsonism Relat Disord · 2024
PMID: 39326285Observational
The effects of chronic administration of tranylcypromine and rimonabant on behaviour and protein expression in brain regions of the rat.
Assareh Neda, ElBatsh Maha M, Marsden Charles A et al. · Pharmacol Biochem Behav · 2012
PMID: 22037406Observational
Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents.
Hill Matthew N, Ho Wing-Sze Vanessa, Hillard Cecilia J et al. · J Neural Transm (Vienna) · 2008
PMID: 18974922ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tranylcypromine (substance)
SNOMED CT
372891006
UMLS CUI
C0040778
RxNorm CUI
10734

Clinical Data

This intervention maps to 8 entities in the Healos knowledge graph.

2
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
48
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.